Fig. 2From: Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malariaArtefenomel AUC0–∞ and ferroquine AUC0–d28 distribution across treatment groups. PK/PD efficacy populationBack to article page